Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by JLGeminion May 11, 2011 12:17pm

374 Views

Post# 18560486

The Real News - Hold and Buy Oncolytics

The five posts CravenRaven and mewland have made today are a real coincidence. Their content has little importance but does serve the purpose of burying the discussion on this mornings’ announcement.

I viewed the announcement as positive and posted Rounding the Post. It is repeated in italics to get it back to the top of the Board.

Today’s AGM will be different than prior ones. This morning’s timed announcement of the supply agreement is another indication that the commercialization of Reolysin is rounding the corner to the home stretch. AMGN paid $1 billion for Biovex. The market cap of ONC is under $390 million. The days of the buy side manipulation are coming to an end and the shorts have limited time to cover their bets. Hold and buy Oncolytics. How many trading days until the World Lung Cancer Conference?

Sharkfood posted his disagreement. He is welcome to it. I did not understand it.

If a reader listens to the interview Pericles posted under A Must Listen, the announcement is exciting news but not a surprise. Brad said that Oncolytics was moving forward to start stock piling Reolysin in advance of being granted FDA approval. The announcement also addresses cost of manufacturing concerns, and shows confidence in getting FDA approval on the manufacturing side. As for partnership agreements, I like the concept of licensing agreements with a third party doing the manufacturing. It maximizes the number of therapies that Reolysin can be paired and Oncolytics maintains control.

It is the readers’ choice to side with Sharkfood’s judgment or mine. I know CravenRaven and mewland will side with Sharkfood and support the buy side manipulation. As an example of a buy side manipulation, here is the trading of Dendreon.

Trading of Dendreon, DNDN, on the NASDAQ

Date	Close	Volume

31-Dec-08	4.58	714,221
15-Jan-09	4.61	2,471,820
30-Jan-09	3.37	1,317,839
17-Feb-09	3.65	1,606,247
27-Feb-09	3.05	2,757,763
16-Mar-09	3.95	4,921,467
31-Mar-09	4.20	2,296,321
01-Apr-09	4.14	3,199,650
02-Apr-09	4.34	2,427,867
03-Apr-09	5.99	22,497,200
06-Apr-09	6.58	19,585,750
07-Apr-09	6.58	7,346,062
08-Apr-09	6.37	5,392,639
09-Apr-09	6.30	4,234,697
13-Apr-09	7.30	12,775,310
14-Apr-09	16.99	65,120,890
15-Apr-09	17.17	19,294,060
16-Apr-09	17.03	6,894,881
17-Apr-09	17.99	17,799,470
20-Apr-09	19.52	17,724,250
21-Apr-09	19.74	11,008,510
22-Apr-09	20.12	7,358,435
23-Apr-09	20.33	6,123,418
24-Apr-09	20.08	7,393,327
27-Apr-09	21.55	18,569,850
28-Apr-09	11.81	28,070,740
29-Apr-09	22.94	48,235,790
30-Apr-09	21.20	17,468,950
Yesterday
10-May-11	39.04	2,245,713